It has come to our attention that between 13 June 2023 and 2 November 2023, the drug-drug interaction records for idelalisib contained information and recommendations relating to another drug (infigratinib). We apologise sincerely for this error. The interaction records have been revised and we are putting in place preventative actions.
Physicians who used our checker during this period are asked to review patients receiving idelalisib (or for whom idelalisib might have been considered) with boosted ARVs, efavirenz, etravirine, nevirapine (where the correct recommendation should have been AMBER instead of RED) or maraviroc (where the correct recommendation should have been to reduce maraviroc dose in patients with impaired eGFR [guidelines differ - see https://www.hiv-druginteractions.org/interactions/144183]).
If you are a patient receiving idelalisib and have any concerns please consult your usual physician.